DK1309355T3 - Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber - Google Patents

Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber

Info

Publication number
DK1309355T3
DK1309355T3 DK01960612T DK01960612T DK1309355T3 DK 1309355 T3 DK1309355 T3 DK 1309355T3 DK 01960612 T DK01960612 T DK 01960612T DK 01960612 T DK01960612 T DK 01960612T DK 1309355 T3 DK1309355 T3 DK 1309355T3
Authority
DK
Denmark
Prior art keywords
lys
peptide
molecule
group
po3h2
Prior art date
Application number
DK01960612T
Other languages
English (en)
Inventor
Michel Dard
Guenter Hoelzemann
Horst Kessler
Joerg Meyer
Berthold Nies
Martin Kantlehner
Ulrich Hersel
Christoph Gibson
Gabor Sulyok
Original Assignee
Biomet Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomet Deutschland Gmbh filed Critical Biomet Deutschland Gmbh
Application granted granted Critical
Publication of DK1309355T3 publication Critical patent/DK1309355T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
DK01960612T 2000-08-17 2001-08-02 Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber DK1309355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040105A DE10040105A1 (de) 2000-08-17 2000-08-17 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
PCT/EP2001/008932 WO2002013872A1 (de) 2000-08-17 2001-08-02 Peptid- und peptidmimetikakonjugate mit integrin-inhibitor-eigenschaften

Publications (1)

Publication Number Publication Date
DK1309355T3 true DK1309355T3 (da) 2008-08-25

Family

ID=7652668

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01960612T DK1309355T3 (da) 2000-08-17 2001-08-02 Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber

Country Status (19)

Country Link
US (1) US7655624B2 (da)
EP (1) EP1309355B9 (da)
JP (1) JP4902090B2 (da)
KR (1) KR20030062319A (da)
CN (1) CN1447699A (da)
AT (1) ATE395085T1 (da)
AU (1) AU2001282059A1 (da)
CA (1) CA2419423C (da)
CY (1) CY1108898T1 (da)
CZ (1) CZ2003692A3 (da)
DE (2) DE10040105A1 (da)
DK (1) DK1309355T3 (da)
ES (1) ES2306723T3 (da)
HU (1) HUP0301396A2 (da)
MX (1) MXPA03001428A (da)
PL (1) PL358809A1 (da)
PT (1) PT1309355E (da)
WO (1) WO2002013872A1 (da)
ZA (1) ZA200302049B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
WO2002040073A1 (en) * 2000-11-20 2002-05-23 Université De Genève Endosseous implant
DE10325049A1 (de) * 2003-06-02 2004-12-23 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
EP2255832A3 (en) * 2004-06-16 2011-02-09 Affinergy, Inc. IFBM's to promote attachment of target analytes
WO2008143933A1 (en) * 2007-05-15 2008-11-27 Cvpath Institute, Inc. Coating stents with integrin selective peptides or mimetics
KR102017026B1 (ko) * 2013-01-10 2019-09-02 (주) 수파드엘릭사 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0983095B1 (de) * 1997-05-22 2004-09-29 Biomet Deutschland GmbH Peptid-beschichtete implantate und verfahren zu ihrer herstellung
DE19755801A1 (de) 1997-12-16 2000-06-21 Merck Patent Gmbh Mit die Zelladhäsion vermittelnden Peptiden beschichtete Implantate und Verfahren zu ihrer Herstellung
DE19755800A1 (de) 1997-12-16 1999-06-17 Merck Patent Gmbh Cyclopeptidderivate
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
DE19932796A1 (de) 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
US20070137128A1 (en) 2005-12-02 2007-06-21 Nicolas Viau Modular stone panel

Also Published As

Publication number Publication date
US7655624B2 (en) 2010-02-02
HUP0301396A2 (hu) 2003-09-29
CY1108898T1 (el) 2014-07-02
ZA200302049B (en) 2004-08-27
CA2419423A1 (en) 2002-02-21
PL358809A1 (en) 2004-08-23
CA2419423C (en) 2011-01-04
EP1309355B9 (de) 2009-04-08
MXPA03001428A (es) 2003-06-06
KR20030062319A (ko) 2003-07-23
DE10040105A1 (de) 2002-02-28
ATE395085T1 (de) 2008-05-15
AU2001282059A1 (en) 2002-02-25
DE50113975D1 (de) 2008-06-26
JP2004506024A (ja) 2004-02-26
WO2002013872A1 (de) 2002-02-21
CZ2003692A3 (cs) 2003-06-18
EP1309355A1 (de) 2003-05-14
PT1309355E (pt) 2008-08-26
EP1309355B1 (de) 2008-05-14
ES2306723T3 (es) 2008-11-16
JP4902090B2 (ja) 2012-03-21
US20040029782A1 (en) 2004-02-12
CN1447699A (zh) 2003-10-08

Similar Documents

Publication Publication Date Title
DK1309355T3 (da) Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber
MXPA03007358A (es) Transportadores que contienen porciones de arginina separadas.
DE60031999D1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
HUT75708A (en) Neurokinine (tachykinine) antagonists
TW222642B (da)
MY119155A (en) New peptide derivatives
MY116947A (en) Protease inhibitors
DE3784799D1 (de) Malonsaeurederivate und ihre synthesemethoden.
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
CA2280727A1 (en) Bicyclic amino acids
ATE430165T1 (de) Peptide mit integrinbindungsmotiv und behandlungsmethoden für muskelkrankheiten
MY149831A (en) Stable pharmaceutical composition containing factor viii
US5231082A (en) Cyclic peptide with anti-metastasis activity
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
DE69626671D1 (de) Fusionsproteine bestehend aus gewebefaktor-kunitzdomäne als inhibitoren des faktors viia
NO955067D0 (no) FVII/TF peptider
CA2315532A1 (en) Cyclopeptide derivatives with integrin inhibitor properties
JP2004506024A5 (da)
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
CY1108945T1 (el) Παραγωγα πεπτιδιων και πεπτιδομιμητικων ενωσεων με ιδιοτητες αναστολεα ενσωματινης ιι
NZ519062A (en) Peptides for treatment of erectile dysfunction
ATE528287T1 (de) Nicht peptidische rgd-analoga mit adhäsions-, migrations- und proliferationshemmender wirkung
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
MY119431A (en) (het)arysulfonylureas having an amino function, their preparation and their use as herbicides and plant growth regulators
ECSP993211A (es) Inhibidores de proteasas vi